CN112105384B - 癌糖肽的单克隆和人源化抗体 - Google Patents

癌糖肽的单克隆和人源化抗体 Download PDF

Info

Publication number
CN112105384B
CN112105384B CN201780083837.9A CN201780083837A CN112105384B CN 112105384 B CN112105384 B CN 112105384B CN 201780083837 A CN201780083837 A CN 201780083837A CN 112105384 B CN112105384 B CN 112105384B
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
sequence shown
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780083837.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN112105384A (zh
Inventor
周大鹏
P.胡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Qihang Nano Pharmaceutical Co ltd
University of Texas System
Original Assignee
Suzhou Qihang Nano Pharmaceutical Co ltd
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Qihang Nano Pharmaceutical Co ltd, University of Texas System filed Critical Suzhou Qihang Nano Pharmaceutical Co ltd
Publication of CN112105384A publication Critical patent/CN112105384A/zh
Application granted granted Critical
Publication of CN112105384B publication Critical patent/CN112105384B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201780083837.9A 2017-01-18 2017-01-18 癌糖肽的单克隆和人源化抗体 Active CN112105384B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/071546 WO2018132976A1 (en) 2017-01-18 2017-01-18 Monoclonal and humanized antibodies to a cancer glycopeptide

Publications (2)

Publication Number Publication Date
CN112105384A CN112105384A (zh) 2020-12-18
CN112105384B true CN112105384B (zh) 2024-08-23

Family

ID=62907489

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780083837.9A Active CN112105384B (zh) 2017-01-18 2017-01-18 癌糖肽的单克隆和人源化抗体

Country Status (5)

Country Link
US (1) US11673966B2 (https=)
EP (1) EP3570881A4 (https=)
JP (1) JP7162011B2 (https=)
CN (1) CN112105384B (https=)
WO (1) WO2018132976A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119431585A (zh) * 2024-11-19 2025-02-14 恩替(苏州)生物科技有限公司 一种抗人muc1抗体的制备方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103880956A (zh) * 2014-03-10 2014-06-25 中国人民解放军第四军医大学 抗muc1单克隆抗体及其轻链和重链可变区

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1182210A1 (en) * 2000-08-17 2002-02-27 BASTERT, Gunter, Prof.Dr.med.Dr.h.c. Epitopes of tumor-associated MUC1 antigen
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
WO2011127219A1 (en) * 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
JP2013540995A (ja) * 2010-08-18 2013-11-07 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 疾患に対する循環バイオマーカー
WO2012115885A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
CN105592861A (zh) * 2013-08-02 2016-05-18 赛诺菲 抗Muc1类美登素免疫偶联抗体用于治疗实体瘤的用途
US11753619B2 (en) * 2017-02-02 2023-09-12 The Scripps Research Institute Engineered cells and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103880956A (zh) * 2014-03-10 2014-06-25 中国人民解放军第四军医大学 抗muc1单克隆抗体及其轻链和重链可变区

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Antibody targeting of cell-bound MUC1 SEA domain kills tumor cells;Edward Pichinuk等;CANCER RES;第72卷(第13期);第3324-3336页 *

Also Published As

Publication number Publication date
US11673966B2 (en) 2023-06-13
CN112105384A (zh) 2020-12-18
JP7162011B2 (ja) 2022-10-27
EP3570881A4 (en) 2020-08-19
WO2018132976A1 (en) 2018-07-26
US20200115466A1 (en) 2020-04-16
EP3570881A1 (en) 2019-11-27
JP2020507338A (ja) 2020-03-12

Similar Documents

Publication Publication Date Title
JP7425604B2 (ja) 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用
CN111454357B (zh) 一种含有抗体的肿瘤治疗剂的开发和应用
TWI840433B (zh) 新穎合理設計的蛋白質組合物
EP4461746A2 (en) Anti-pd-1/vegfa bifunctional antibody, pharmaceutical composition thereof and use thereof
JP4854912B2 (ja) 癌に対する抗体
JP5795538B2 (ja) ヒトのラミニン５アルファ３鎖のｌｇ４−５ドメインに対するモノクローナル抗体
WO2017148424A1 (zh) 一种pdl-1抗体、其药物组合物及其用途
JP2021527714A (ja) 抗ｐｄ−１抗体及びその使用
WO2018036472A1 (zh) 一种抗pd1单克隆抗体、其药物组合物及其用途
JP2013502913A5 (https=)
HUE026846T2 (en) Antibodies to Recognize Carbohydrate-Containing Epitope on CD43 and CEA Expressed on Cancer Cells and Procedures for their Use
HUP0401695A2 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
AU2002240719A1 (en) Antibodies against cancer
CN112513088A (zh) 抗ox40抗体、其抗原结合片段及其医药用途
RU2533460C2 (ru) Фармацевтическая композиция для лечения и предупреждения рака
CN107001452A (zh) 用于治疗癌症的抗ck8抗体
WO2019109947A1 (zh) 抗人il6单克隆抗体及其制备方法和用途
WO2024051223A1 (zh) 药物组合及用途
CN112105384B (zh) 癌糖肽的单克隆和人源化抗体
JP2007252372A (ja) モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ、医薬組成物ならびに診断試薬
JP2020150947A (ja) 抗ポドプラニン抗体
CN118108842A (zh) 人源化抗cd24抗体及其应用
JPWO2020218951A5 (https=)
WO2025146161A1 (en) Antibody, antigen-binding fragment and medical use thereof
RU2782462C1 (ru) Новое антитело против ccr8

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant